The Engine of
Phage Innovation

Revolutionizing healthcare with faster, affordable, and scalable phage solutions.

OUR SUPPORTERS

Technology

Accelerating
Precision Antibiotics

At Biophoundry, we are harnessing the unique properties of phages to drive a new wave of innovation in therapeutics, diagnostics, and next-generation bio-molecular engineering.

This resurgence of phage-based technologies marks a pivotal moment in biotech, enabling faster, scalable, and more precise solutions.

As we push the boundaries of what’s possible, our mission is to redefine the future of molecular biology and accelerate the next generation of precision antibiotics.

Green glass-metallic background with statistic cards

Our team

Meet our Team

Our multidisciplinary team combines expertise in synthetic biology, robotics, and data science to tackle one of the world’s most pressing challenges.

Rani Brooks

CEO & Co-Founder

Rani brings 15 years of research experience across government, academia, and industry. Holding a Bioinnovation PhD from Tulane University, he secured two core technology patents for Biophoundry. As Tulane’s first Innovation Postdoctoral Fellow, he advanced IP commercialization, now embodied in Biophoundry.

Sahan Liyanagedera

CTO & Co-Founder

Sahan, a PhD in Systems Engineering and Synthetic Biology from the University of Warwick, pioneered the SpyPhage Platform for rapid, cell-free bacteriophage production. His research focuses on synthetic biology, phage engineering, and optimizing cell-free TXTL systems.

Nancy Kim

Senior Scientist

Nancy has extensive expertise in developing synthetic biology tools for both model and non-model microorganisms. She earned her PhD through the Bioinnovation PhD program at Tulane University prior to a post doctoral position at the FDA. At Biophoundry, she works on the development and validation of the Phax Platform.

Sahan Liyanagedera

Michael Stam

CTO & Co-Founder

Senior ML Scientist

Michael, with a PhD in Biomedical AI from the University of Edinburgh, developed ML tools to rank protein designs for novel enzymes and therapeutics. Now at Biophoundry, he advances and validates the cutting-edge Phax platform.

Nancy Kim

Senior Scientist

Michael Stam

Senior ML Scientist

News

Recent Developments

Stay updated with the latest breakthroughs from Biophoundry. From advancements in our Phax platform to impactful research in phage engineering, explore how we’re driving innovation to make phage therapy faster, more accessible, and cost-effective for global healthcare challenges.